Nrf2 activator - AstraZeneca
Latest Information Update: 14 Jul 2025
At a glance
- Originator C4X Discovery
- Developer AstraZeneca; C4X Discovery
- Class Anti-inflammatories; Antianaemics; Small molecules
- Mechanism of Action NF-E2-related factor 2 stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Inflammation
Most Recent Events
- 28 Nov 2022 AstraZeneca in-license oral Nrf2 activators for development and commercialisation in Chronic obstructive pulmonary disorder in Worldwide
- 01 Oct 2019 Preclinical trials in Sickle cell anaemia in United Kingdom (PO)
- 27 Sep 2019 Preclinical trials in Chronic obstructive pulmonary disease in United Kingdom (PO)